Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Researchers at Pfizer Release New Data on Vaccines (Development of a subunit vaccine for prevention of Clostridium difficile associated diseases:...

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 10:57pm CEST

Researchers at Pfizer Release New Data on Vaccines (Development of a subunit vaccine for prevention of Clostridium difficile associated diseases: Biophysical characterization of toxoids A and B)

By a News Reporter-Staff News Editor at Vaccine Weekly -- New research on Immunization - Vaccines is the subject of a report. According to news reporting originating in Pearl River, New York, by NewsRx journalists, research stated, "Inactivation of bacterial toxins for use in human vaccines traditionally is achieved by treatment with formaldehyde. In contrast, the bivalent experimental vaccine for the prevention of infections (CDI) that is currently being evaluated in clinical trials was produced using a different strategy. toxins A and B were inactivated using site-directed mutagenesis and treatment with 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride/-hydroxysulfosuccinimide (EDC/NHS)."

The news reporters obtained a quote from the research from Pfizer, "In the present work we investigate the effect of genetic and chemical modifications on the structure of inactivated toxins (toxoids) A and B. The far-UV circular dichroism (CD) spectra of wild type toxins, mutated toxins, and EDC/NHS-inactivated toxoids reveal that the secondary structure of all proteins is very similar. The near-UV CD spectra show that aromatic residues of all proteins are in a unique asymmetric environment, indicative of well-defined tertiary structure. These results along with the fluorescence emission maxima of 335?nm observed for all proteins suggest that the tertiary structure of toxoids A and B is preserved as well. Analytical ultracentrifugation data demonstrate that all proteins are predominantly monomeric with small fractions of higher molecular weight oligomeric species present in toxoids A and B. Differential scanning calorimetry data reveal that genetic mutations induce thermal destabilization of protein structures. Subsequent treatment with EDC/NHS results either in a minimal (1??C) increase of apparent thermostability (toxoid B) or no change at all (toxoid A)."

According to the news reporters, the research concluded: "Therefore, our two-step inactivation strategy is an effective approach for the preparation of non-toxic proteins maintaining native-like structure and conformation."

For more information on this research see: Development of a subunit vaccine for prevention of Clostridium difficile associated diseases: Biophysical characterization of toxoids A and B. Biochemistry and Biophysics Reports, 2017;9():193-202 (see also Immunization - Vaccines).

Our news correspondents report that additional information may be obtained by contacting A. Gribenko, Pfizer Vaccine Research and Development, 401 N Middletown Road, Pearl River, NY 10965, United States. Additional authors for this research include E. Severina, M.K. Sidhu, K.U. Jansen, B.A. Green and Y.V Matsuka.

The direct object identifier (DOI) for that additional information is: http://dx.doi.org/10.1016/j.bbrep.2016.12.015. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: New York, Genetics, Vaccines, Pearl River, Immunization, United States, Biological Products, Risk and Prevention, Clostridium difficile, Gram Positive Bacteria, North and Central America, Gram Positive Endospore Forming Rods, Gram Positive Endospore Forming Bacteria.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on PFIZER
10/19 PFIZER : U.S. FDA Approves LYRICA® CR pregabalin Extended-Release Tablets CV
10/19 PFIZER : Reports on Structural Biology from Pfizer Provide New Insights (Develop..
10/19 PFIZER : Reviewing Strategic Alternatives for Consumer Healthcare Business
10/19 PFIZER : Reports from Pfizer Highlight Recent Findings in Amino Acid Receptors [..
10/19 PFIZER : New Estrogen Study Results from Pfizer Described (Pharmacokinetics, Dos..
10/19 PFIZER : Centreone Expands Contract Manufacturing To Nagoya, Japan
10/19 PFIZER : Biopharmaceutical Industry Creates Economic Opportunity for Americans
10/19 PFIZER : EDGE board approves incentives to entice Amazon warehouse, Pfizer jobs
10/18 PFIZER : Pfizers lorlatinib impresses in Phase II lung cancer trial
10/18 PFIZER INC. : Phase II Clinical Trial Of Lorlatinib Shows Promise
More news
News from SeekingAlpha
04:16a Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2017 Update
10/19 A KISS Dividend Strategy Worth 15% A Year
10/18 Only 16 Of 61 Are 'Safer' Dividend Healthcare Dogs For October
10/18 HEALTHCARE DOGFIGHT : Owens & Minor Edges GlaxoSmithKline As Top Broker Pick For..
Financials ($)
Sales 2017 52 694 M
EBIT 2017 19 840 M
Net income 2017 11 410 M
Debt 2017 24 099 M
Yield 2017 3,54%
P/E ratio 2017 19,51
P/E ratio 2018 16,93
EV / Sales 2017 4,55x
EV / Sales 2018 4,36x
Capitalization 216 B
Duration : Period :
Pfizer Technical Analysis Chart | PFE | US7170811035 | 4-Traders
Technical analysis trends PFIZER
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 38,3 $
Spread / Average Target 5,7%
EPS Revisions
Ian C. Read Chairman & Chief Executive Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Dennis Arthur Ausiello Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER11.58%213 372
JOHNSON & JOHNSON23.29%377 585
NOVARTIS13.50%226 453
ROCHE HOLDING LTD.5.55%215 760
AMGEN27.41%135 924